This promising advance in the development of cell-based therapies to treat liver failure resulting from injury or disease relied on the development of scalable, reproducible methods to produce stem cell-derived hepatocytes in bio-reactors, researchers said.
Massoud Vosough and coauthors demonstrate, in an article described in the journal Stem Cells and Development, a large-scale, integrated manufacturing strategy for generating functional hepatocytes in a single suspension culture grown in a scalable stirred bio-reactor.
The researchers "developed a system for mass manufacture of stem cell derived hepatocytes in numbers that would be useful for clinical application," creating possibilities for future "immune matched cell based therapies," said David C Hay from the University of Edinburgh, UK.
Such approaches could be used to correct mutated genes in stem cell populations prior to differentiation and transplantation, Hay said.
